“…Although some studies have not observed a statistically significant increase in excessive uterine activity with their concurrent use, this is likely due to the small number of patients in these studies, differences in methodology (eg, uterine activity was not continuously monitored), and the relatively low frequency of this adverse event. [28][29][30] In one such trial, the frequency of uterine tachysystole with concurrent dinoprostone and oxytocin administration was 14% versus 5% with oxytocin alone (P ¼ .20). 28 The incidence of meconium passage and mean blood loss were similar in the two groups, further confirming the safety of both treatments.…”